Objective. This study explored the putative mechanisms of miRNAs in the anterior cingulate cortex (ACC) in modulation of neuropathic pain induced by chronic constriction injury (CCI) of the sciatic nerve.
Introduction
Chronic neuropathic pain has become a severe public health problem that affects approximately up to 40% of the general population [1, 2] . It is characterized as allodynia and hyperalgesia in response to nonpainful or noxious stimuli, respectively due to the damage or abnormal function of the nervous system [3, 4] , resulting in pathological pain that can persistent for a long period of time [5, 6] . However, the molecular mechanisms underlying neuropathic pain are still largely unknown.
The anterior cingulate cortex (ACC) in the brain is an important brain region of the limbic system, which is thought to be critical for emotional and attentive responses to the noxious stimuli [7] [8] [9] . Increasing evidence from both human and animal studies has shown that the ACC plays an important role in mediating the sensational component of physiological and pathological pain. For example, electrical stimulation or local lesion of the ACC can remarkably reduce acute nociceptive responses, reduce chronic pain in patients, and attenuate mechanical allodynia in rats with neuropathic pain [10, 11] .
Emerging evidence has demonstrated that persistent alterations of neuronal excitability associated with intrinsic plasticity in the ACC are critical formodulations of chronic pain [12] [13] [14] . Furthermore, it has been shown that functional regulation of NMDA receptors and their downstream signaling cascades are critical for the alterations of neuronal excitability [15, 16] . In fact, previous studies have shown that NR2B-containing NMDA receptor-mediated neuronal plasticity in the ACC contributes to inflammation-related or nerve injury-related neuropathic pain [17] [18] [19] [20] . While there is evidence that chronic pain alters the expression of NR2B-containing receptors differently between contralateral and ipsilateral ACC [21] , little is known about the function of NR2B-containing receptors within the contralateral and ipsilateral ACC in modulation of chronic neuropathic pain.
Recent studies have indicated that microRNAs (miRNAs) have been implicated in the regulation of neuropathic pain [22] . MiRNAs are a subset of noncoding functional RNAs with a length of 18 to 24 nucleotides that can target mRNA, leading to mRNA destabilization and degradation [23] [24] [25] . It has been demonstrated that numerous miRNAs expressed in the nervous system are involved in neuroinflammation and neuropathic pain [26] [27] [28] . For instance, studies have indicated that miR-539 and miR223are highly expressed in the brain and are involved in modulation of the NR2B subunit of NMDA receptor expression [29, 30] . However, no studies have been conducted to examine the role of miRNAs in the ACC in modulation of chronic neuropathic pain. Therefore, this study was designed to examine the effects of chronic neuropathic pain on the levels of miRNAs in the ACC. Furthermore, we used molecular and behavioral approaches to examine the role of miR-539 in the ACC in modulation of NR2B subunit expression and neuropathic pain induced by chronic constriction injury (CCI) of the sciatic nerve.
Methods

Animals
Male Sprague-Dawley rats (Charles River Laboratories, Beijing, China) weighing 150 to 200 g (N ¼ 20) were used in this study. We focused on male rats because previous studies have demonstrated that there is sex difference in the mechanisms of CCI-induced neuropathic pain [31, 32] . Upon arrival, rats were acclimated in the Animal Center of Wuxi No. 2 People's Hospital for one week before subsequent experiments. All rats were housed in separated cages in a room with a 12:12 light cycle, with 21.0 C to 23.0 C and 50% to 60% humidity, and were given food and water ad libitum. All animal experiments in the present study had been approved by the Institutional Animal Care and Use Committee of Wuxi No. 2 People's Hospital. The housing and treatment of the rats followed the guidelines of the "Guide for the Care and Use of Laboratory Rats" (Institute of Laboratory Animal Resources, Commission on Life Sciences 2012).
Chronic Constriction Injury of the Sciatic Nerve
Neuropathic surgery was done on rats under full anesthesia using ketamine/xylazine (80-120 mg/kg, 10-16 mg/kg, respectively, i.p.). Surgeries were conducted on the left side of the rat, and the contralateral side was left intact. Rats were subjected to chronic constriction injury (CCI) based on the method described previously [33] ; 4 Â 4-0 chronic sutures were used to loosely tie around the sciatic nerve so as to barely constrict blood flow. Animals were maintained for up to 14 days after CCI. Sham control animals underwent the same surgery without constriction around the sciatic nerve. The incision was closed in layers, and the wound was treated with antibiotics (penicillin). All experimental work involving animals conformed to the International Association for the Study of Pain guidelines on animals in pain research. We made all efforts to minimize the number of animals used and their suffering.
Stereotaxic Surgery
Immediately after neuropathic surgery, rats were placed in a stereotaxic apparatus (Stoelting, Wood Dale, IL, USA). The scalp was first incised, and the skull was leveled off around the bregma. Two 24 gauge, 10 mm stainless steel guide cannulae were bilaterally implanted 1 mm over the right and left ACC according to the following coordinates: 2.4 mm anterior to the bregma, 0.6 mm left and right sides of the midline, and 1.3 mm below the top of the skull. The cannulae were then fixed to the skull using three screws and dental acrylic. To keep cannulae patent prior to microinjection, 10 mm stylets were inserted to cannulae. All animals were allowed five days to recover from surgery.
Intracranial Microinjection
A 30 gauge, 11 mm injection needle attached to a 30 cm polyethylene tube fitted to a 1 ll Hamilton syringe was used for intra-ACC microinjections. The volume of the drug solution to be injected into each ACC was 0.25 ll, and the injection was slowly made over a period of two minutes. The injection needle was left in place for an additional one minute before and after the injection.
Separate groups of rats were used for different experiments. Specifically, for examining the role of miRNAs in CCI-induced neuropathic pain (N ¼ 8-9/group/hemisphere), contralateral or ipsilateral intra-ACC microinjections of miRCURY LNA microRNA mimics of miR-539 (CATACAAGGGTAATTTCTTTTC, #470108-001; Exiqon, Woburn, MA, USA) or a scrambled control (#199004-11; Exiqon, Woburn, MA, USA) were conducted seven days after CCI-induced nerve injury. miRNAs were administered at a dose of 2 lg once daily into the ACC from days 8 to 11 after CCI for four consecutive days.
For examining the role of NR2B-containing receptor in the ACC in CCI-induced neuropathic pain (N ¼ 8-9/ dose/hemisphere), contralateral or ipsilateral intra-ACC microinjections of Ro25-6981 (selective NR2B-containing receptor antagonist; 0, 1, or 4 lg/ll) were performed at day 8 after CCI.
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Behavioral Analysis
On test days, rats were placed in the behavioral apparatus and allowed to acclimate to the environment for 30 minutes. Von Frey assay was conducted to test rat sensitivity to a mechanical stimulus. To this end, rats were placed in a clear plastic cage on top of a wire mesh grid that allowed rats to access their hind paws for the duration of the analysis. During the test, an ascending series of von Frey filaments with logarithmically incremental stiffness (0.6-26 g; Stoelting, Wood Dale, IL, USA) were applied perpendicular to the midplantar surface of each hind paw. Each von Frey filament was held about two to three seconds, with a five-minute interval between each application. Fifty percent withdrawal thresholds were determined using the up-down method [34, 35] . Mechanical withdrawal thresholds were analyzed by blind examiners. For some rats with intra-ACC micoinjections of miRNAs, tests were conducted immediately after injections from day 8 to day 14 for seven consecutive days. For some rats with intra-ACC micoinjections of Ro25-6981, tests were conducted immediately after the injections. Immediately after the last test, rats were sacrificed by live decapitation, ACC tissues from each rat were collected using National Institutes of Health (NIH) style Neuro Punches in a cryostat and stored at À80 C, until subsequent biochemical analysis described as follows.
MicroRNA Microarray
We used an miRNA microarray (Agilent Technology), which contains probes for the complete Sanger miRBase 10.0, to screen RNA from rat ACC tissue seven days after CCI in separate groups of animals (N ¼ 10/group). The experiment was duplicated three times. The labeling and hybridization were performed at the Shanghai Biochip Company, according to the protocols of the Agilent miRNA microarray system. Agilent Scan Control software was used for scanning the microarray slides, and Agilent Feature Extraction (FE) software version 10.5.1 was used for image analysis. Microarray data were analyzed using GeneSpring GX v11.0 software (Agilent Technology). Raw data were normalized by Quantile algorithm and analyzed statistically using the two-sample independent group t test, and differences were considered statistically significant by using a cutoff of a 1.5-fold change at a P value of less than 0.05.
Quantitative Real-Time Polymerase Chain Reaction
Separate groups of rats (N ¼ 10/group) were used to confirm the miRNA expression data using microarrays. Seven or 10 days after CCI, total RNA of the ACC tissue was extracted using TRIzol (Invitrogen, Carlsbad, CA, USA) and small RNAs were extracted using miRVana kits (Ambion Inc., Austin, TX, USA) according to the instructions. cDNA was reverse-transcribed using M-MLV reverse transcriptase (Clontech, Palo Alto, CA, USA) and a TaqMan miRNA reverse transcription kit (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's protocol. The quantitative real-time polymerase chain reaction (qRT-PCR) mixture system, which contained cDNA templates (1 ll), primers (2 ll of each of the forward and reverse primers), and SYBR Green qPCR Master Mix (5 ll), was subjected to qRT-PCR quantification. U6 SnRNA was used as the internal reference, and relative gene expression was quantified by the 2
ÀDDCt method.
Western Blot Analysis
Some of the ACC tissues were used for Western blot analysis. The tissue was homogenized using a Dounce homogenizer in 1 mL of lysis buffer (Sigma-Aldrich, St Louis, MO, USA), followed by boiling at 100 C for 10 minutes in a dry heat block. The Biorad DC Protein Assay kit was used to determine the protein concentration of the samples. Proteins were separated on 9% polyacrylamide gel at 120 V for one hour and transferred onto a nitrocellulose membrane at 100 V for one hour. The membrane was then blocked in 3% milk for one hour and incubated with anti-NR2B antibody (1:5000; #05-920, Millipore, Shanghai, China) overnight at 4 C. The membrane was then incubated for one hour with horseradish peroxidase (HRP)-conjugated donkey antirabbit polyclonal secondary antibody (1:10,000, GE Healthcare, Piscataway, NJ, USA). The film was then developed using an enhanced chemiluminescence (ECL) system (Pierce Biotech, Rockford, IL, USA). Stripping buffer (62.5 mM Tris-HCl, pH 6.7, 2% SDS, 100 mM b-mercaptoethanol) was used to wash membrane to allow reprobing with antibodies to actin (1:50,000, #A5441, Sigma, Shanghai, China), which served as a loading control. NIH Image J software was used to quantify proteins by densitometry. Data was analyzed after NR2B levels were normalized to the levels of b-actin, then to control.
Statistical Analysis
Data were expressed as mean 6 SEM. Data were analyzed using unpaired t test, one-way or mixed-factorial analyses of variance (ANOVAs), where appropriate. Significant ANOVA main and interaction effects were further investigated using Tukey or Bonferroni post hoc tests, when appropriate. Alpha was set at 0.05.
Results
Histology
Schematics illustrating cannula placements and representative microimage of coronal brain section outlining the area where the cannula tracks are included in Figure 1 . The most ventral point of the infusion cannula tracks was located within the anterior cingulate cortex (ACC). Furthermore, high-power microscopy did not reveal any evidence of abnormal tissue damage (i.e., extensive cell loss or gliosis) at the infusion site. The sample sizes are reported in the figure captions. Rats miR-539 and Neuropathic Pain (N ¼ 6) with cannula placement outside of the ACC or losing head caps (N ¼ 4) were excluded from the study.
The Effects of CCI on miRNAs Expression in the ACC
We examined the expression of 350 Rattus norvegicusmiRNAs based on Version 10.0 of the Sanger miRBase (Sanger Institute, Cambridge, UK; http://microrna. sanger.ac.uk/sequences) in the ACC seven days after CCI. Using the miRNA-based array screening, we have identified differentially expressed miRNAs in the ACC in rats after CCI, as compared with the sham control rats. The expression of nine miRNAs was enhanced, and the expression of 12 miRNAs was reduced in the ACC in rats seven days after CCI (Table 1) . Of all the altered miRNAs, we were particularly interested in miR-539, which was shown to play a critical role in controlling NR2B subunit expression in the rat brain [30] . Therefore, we decided to examine the role of miR-539 in the ACC in CCI-induced neuropathic pain in the following experiments.
Effects of CCI on the Levels of miR-539 and NR2B Subunit Expression in the ACC
To validate the microarray results on miR539, we assessed the expression of miR-539 in contralateral and ipsilateral ACC using real-time Taqman PCR. The expression of this miRNA analyzed by real-time Taqman PCR was consistent with the microarray results. Specifically, seven or 14 days after CCI, miR-539 levels in the ACC were dramatically reduced in the contralateral ACC (relative to the side of CCI), as compared with sham control rats (t tests, P < 0.01) (Figure 2A) . A mild reduction of miR-539 expression was also seen in the ipsilateral ACC (t tests, P < 0.05) ( Figure 2B ). Furthermore, Western blot analysis showed that seven or 14 days after CCI, NR2B subunit protein levels in the contralateral ACC were robustly increased, as compared with sham control rats (t tests, P < 0.01) ( Figure 2C) . A moderate enhancement of NR2B subunit protein levels was also seen in the ipsilateral ACC (t tests, P < 0.05) ( Figure 2D ).
Effects of Intra-ACC Administrations of miR-539 Mimics on CCI-Induced Mechanical Allodynia
We found that administrations of miR-539 mimics into the contralateral ACC significantly inhibited CCI-induced mechanical allodynia, as compared with control miRNA administration (all ANOVA main and interaction effects, F (2-12,22-132) ¼ 29.75-38.61, P ¼ 0.0001-0.01) ( Figure  3A ).This effect was associated with reduced protein levels of NR2B subunit in the contralateral ACC (one-way ANOVA, P < 0.5) ( Figure 3B ). However, administrations of miR-539 mimics into the ipsilateral ACC did not alter CCI-induced mechanical allodynia, as compared with control miRNA administration ( Figure 3C ). Furthermore, administrations of miR-539 mimics into the ipsilateral ACC did not alter NR2B subunit protein levels ( Figure  3D ).
Effects of Intra-ACC Administrations of Ro25-6981 on CCI-Induced Mechanical Allodynia
To test the function of NR2B-containing NMDA receptor in the ACC in CCI-induced mechanical allodynia, we administered Ro25-6981 into the contralateral or ipsilateral ACC. We found that administrations of Ro25-6981 into the contralateral ACC dose-dependently inhibited CCIinduced mechanical allodynia, as compared with vehicle administration (one-way ANOVA, P < 0.05) ( Figure 4A ). However, administrations of an effective dose of Ro25-6981 (i.e., 4 lg) into the ipsilateral ACC only produced a mild alleviation of CCI-induced mechanical allodynia, as compared with vehicle administration ( Figure 4B ).
Discussion
This study was designed to explore the putative mechanisms of miRNAs in the ACC in modulation of neuropathic pains. Using miRNA microarray, we have identified that the expression of nine miRNAs was enhanced, and the expression of 12 miRNAs, such as miR-539, was reduced in the ACC in rats at post-CCI day 7. We then used real-time PCR to verify that miR-539 expression was robustly decreased in the contralateral ACC and mildly reduced in the ipsilateral ACC. This phenomenon was associated with enhanced protein levels of the NR2B subunit in the ACC in a similar pattern. Furthermore, we found that administrations of miR-539 mimics into the contralateral ACC, but not the ipsilateral ACC, significantly attenuated CCI-induced mechanical allodynia. In addition, administrations of miR-539 mimics into the contralateral ACC, but not the ipsilateral ACC, significantly attenuated NR2B subunit protein levels. These results suggested that exogenous miR-539 may have a greater impact on NR2B subunit expression in the contralateral ACC. Finally, we found that administrations of Ro25-6981 into the contralateral ACC attenuated CCI-induced neuropathic pain, to a greater extent than into the ipsilateral ACC. Together, our results suggested that CCI induces lateralized adaptations of NR2B subunit expression in the ACC, which is likely in part Table 1 Altered microRNA expression 7 days following CCI miR-539 and Neuropathic Pain contributed by alterations of miRNAs expression, and may promote the regulations of neuropathic pain via NR2B-containing NMDA receptor mediated neuronal mechanisms.
An interesting finding is that administrations of miR-539 mimics into the contralateral, but not ipsilateral, ACC attenuated CCI-induced neuropathic pain. Furthermore, administrations of miR-539 mimics into the contralateral, but not ipsilateral, ACC decreased NR2B subunit protein levels. Even in the contralateral ACC, miR-539 mimics did not abolish CCI-induced increase in NR2B protein levels. These results indicated that other mechanisms are also involved in CCI-induced increase in NR2B protein levels in contralateral and ipsilateral ACC. For example, it has been shown that miR-223 deficiency results in higher levels of NR2B in the hippocampus [29] . Given that we have shown that the expression of a number of miRNAs was altered after CCI in the ACC, future studies will be important to explore other putative miRNAs that might also be involved in modulation of CCI-induced neuropathic pain.
Recent studies have demonstrated that a variety of miRNAs play critical roles in regulating pain processing using experimental animal models of neuropathic pain [36] . Specifically, studies have shown that spinal miR-203 is involved in regulating neuropathic pain development through targeting Rap1a and its downstream signal pathways MEK/ERK [37] . Furthermore, it has been demonstrated that miR-195 is increased in the spinal cord following peripheral nerve injury, which can aggravate neuropathic pain by inhibiting autophagy [38] . Additionally, nerve injury can increase miR-21 in the dorsal root ganglion, and inhibition of miR-21 results in attenuation of neuropathic pain in rats [39] . However, most of these studies focused on spinal cord mechanisms, and few studies have explored miRNA-mediated supraspinal mechanisms underlying the regulation of neuropathic pain. Thus, adding to this literature, we reported that miR-539 in the ACC plays a critical role in regulating CCI-induced neuropathic pain.
While our study showed that miR539-mediated reduction of NR2B expression in the contralateral ACC is associated with attenuation of neuropathic pain, stimulation of the NR2B-containing NMDA receptor in either contralateral or ipsilateral ACC results in the attenuation of neuropathic pain. These results suggest that enhanced NR2B expression in contralateral ACC might promote the functional control of pain signaling processing in the contralateral ACC. However, NR2B-containing receptor function is critically regulated by various mechanisms, such as Src family kinase [40] . In fact, several studies have shown that certain miRNAs can regulate Src family kinase expression. For instance, is has been shown that miR-203 can reduce Src family kinase expression [41] . Also, miR-205 can inhibit Src family kinase expression [42] . Surprisingly, our study showed that miR-203 and miR-205 are robustly increased in the ACC. Thus, future studies will be necessary to examine the role of miRNAs that are involved in regulating the function of the NMDA receptor in CCI-induced neuropathic pain.
NMDA receptors undergo plasticity under physiological or pathological conditions [43, 44] . The alterations in NMDA receptor subunit composition may also result in activity-dependent plasticity. Previous studies have shown that overexpression of NR2B-containing NMDA receptors in the forebrain enhances behavioral responses to persistent inflammatory pain [45] . In our study, we demonstrated that CCI-induced neuropathic pain results in upregulation of NR2B receptors in the ACC region, to a greater extent in the contralateral site as compared with the ipsilateral site. While our study focused on the expression of the NR2B subunit, studies have shown that the NR1 and NR2A subunits may also be involved in regulation of neuropathic pain. For example, upregulation of mRNAs of NR1 and NR2A has been shown in the rostral ventromedial medulla after inflammation [46] . Thus, it is likely that other subtypes of NMDA receptors in the ACC are also involved in regulation neuropathic pain, which might explain partly that stimulation of the NR2B-containing receptor using Ro25-6981 in either side of the ACC only attenuates, but does not abolish, the CCI-induced neuropathic pain. Therefore, future studies are necessary to examine the role of other NMDA subunit composition in the ACC in the regulation of CCI-induced neuropathic pain. Figure 3 Effects of intra-anterior cingulate cortex (ACC) administrations of miR-539 mimics on chronic constriction injury (CCI)-induced mechanical allodynia. Mechanical allodynia to stimulation of von Frey filaments was indicated by paw withdrawal threshold in grams. Animals were administered with miR-539 mimics or control miRNA by repeated intra-ACC microinjections into the (A) contralateral ACC or (C) ipsilateral ACC from post-CCI day 8 through day 11 for four consecutive days. Paw withdrawal threshold was determined daily from post-CCI day 8 through day 14. ACC brain tissues were collected immediately after the last behavioral test at post-CCI day 14, and protein levels of NR2B subunit in the (B) contralateral ACC or (D) ipsilateral ACC were determined using Western blot.
*
Significant difference relative to sham rats (*P < 0.05, **P < 0.01). † Significant difference relative to rats with control miRNAs ( † P < 0.05). Significant difference relative to rats with vehicle ( † P < 0.05).
